Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01074424|
Recruitment Status : Unknown
Verified February 2010 by National Cancer Institute (NCI).
Recruitment status was: Not yet recruiting
First Posted : February 24, 2010
Last Update Posted : February 24, 2010
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers in blood samples from patients with invasive cervical cancer.
|Condition or disease||Intervention/treatment|
|Cervical Cancer||Genetic: proteomic profiling Other: laboratory biomarker analysis|
- To develop a serum proteomic profile for cervical cancer using banked pre-treatment serum specimens from patients with invasive cervical cancer and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis.
- To develop a serum proteomic profile for cervical cancer using banked post-treatment serum specimens from these patients and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis.
OUTLINE: This is a multicenter study.
Banked serum specimens are used to generate proteomic profiles.
|Study Type :||Observational|
|Estimated Enrollment :||84 participants|
|Official Title:||Development of a Serum Proteomic Profile for Cervical Cancer With Potential Prognostic Value|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||March 2010|
- Generation of a serum proteomic profile using banked pre-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and progression-free survival [PFS])
- Generation of a serum proteomic profile using banked post-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and PFS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01074424
|Principal Investigator:||Samir N. Khleif, MD||National Cancer Institute (NCI)|